Reading this on a mobile device? Try our optimized mobile version here:

May 1, 2012
Companies such as Coca Cola, Goodyear Tire and United Airlines are using industrial biotechnology processes to improve everyday products. Read about it on BIOtechNOW.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at

  Today's Top Story 
  • BIO World Congress highlights potential of bio-based production
    Bio-based products can have the exact chemical makeup of those based on petroleum but with more stable prices. That's one of the messages of the BIO World Congress on Industrial Biotechnology & Bioprocessing this week in Orlando. Among the products on display were a dress shirt and food containers made from corn and carpet made from soybeans. Orlando Sentinel (Fla.) (4/30) LinkedInFacebookTwitterEmail this Story
  Health Care & Policy 
  • Biopharmaceutical firms forge relationships with CROs
    More biopharmaceutical companies are outsourcing clinical trials and research and development to contain costs, comply with regulations and gain access to enough patients for studies to go forward, a Booz & Co. survey found. Moreover, foreign regulators increasingly want to know how a drug performs locally, partner Matthew Le Merle said. Contract research organizations provide qualified employees temporarily, help small companies expand capacity during peak periods, offer noncore services and act as strategic partners in development, another Booz survey found. Genetic Engineering & Biotechnology News (4/30) LinkedInFacebookTwitterEmail this Story
  • Avastin and Lucentis are effective for AMD, study finds
    Genentech's eye drugs Avastin and Lucentis were about equally effective at preserving the vision of elderly people with a form of age-related macular degeneration during a two-year, government-funded study. Patients who received Avastin, however, experienced more complications than the Lucentis group. The Wall Street Journal (4/30) LinkedInFacebookTwitterEmail this Story
  • Targeting gene pathway may aid in diabetes treatment
    A study in the journal Cell found that mice lacking the MED13 gene pathway in the heart were more susceptible to diet-induced obesity and showed abnormal blood glucose metabolism, while mice with higher levels of MED13 were lean and showed an increase in energy expenditure. Researchers said the finding that the heart can regulate systemic metabolism opens up new possibilities for obesity, diabetes and heart disease treatment. Yahoo!/Asian News International (4/27) LinkedInFacebookTwitterEmail this Story
  Company & Financial News 
  • Hologic boosts presence in molecular Dx market with Gen-Probe buy
    Hologic has agreed to acquire Gen-Probe, which specializes in molecular diagnostics, for $3.7 billion. Hologic President and CEO Rob Cascella said the deal allows his company to solidify its position in diagnostics for sexually transmitted diseases, advance its core women's health business and bolster its presence in the global molecular diagnostics space. Mass High Tech (Boston) (4/30) LinkedInFacebookTwitterEmail this Story
  Global Developments 
  • EU regulators OK Luminex's newborn screening technology
    Luminex has earned CE Mark approval to market its NeoPlex System and xMAP NeoPlex4 Assay in Europe. The system enhances newborn screening by offering four tests from one blood spot punch, while the assay can simultaneously test four analytes that may signal risks for congenital hypothyroidism, congenital adrenal hyperplasia and cystic fibrosis. Reuters (4/26) LinkedInFacebookTwitterEmail this Story
  Featured Content 

  Food & Agriculture 
  Industrial & Environmental 
  • EU officials to debate impact of biofuels policy
    EU officials are planning to discuss this week whether the region's biofuels policy contributes to or detracts from its carbon-emissions reduction targets. In preparation for the discussion, a draft compromise proposal that includes a discussion on indirect land-use change impact is being developed. Some environmentalists are urging the EU to consider ILUC in its biofuels policy, but supporters warn that doing such could adversely affect the industry's growth. The Wall Street Journal/Dow Jones Newswires (4/27) LinkedInFacebookTwitterEmail this Story
  News from BIO 
  • BIOtechNOW
    BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the BIOtechNOW e-newsletter. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

It may be that those who do most, dream most."
--Stephen Butler Leacock,
British-Canadian political economist and humorist

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Account Director:  Meryl Harold (202) 407-7828
A powerful website for SmartBrief readers including:
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2012 SmartBrief, Inc.® Legal Information